LigaChem Biosciences

LigaChem Biosciences, based in Daejeon, South Korea, is a biotechnology company. LigaChem Biosciences is a biotech company focused on drug research and development, specialising in antibody-drug conjugate (ADC) therapeutics, small molecule immunotherapies and synthetic drug development. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing LCB02A and LCB84. The largest, NCT05941507 (A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumours), plans to enrol 300 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.